Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Abeona Therapeutics, Inc. (ABEO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.91-7.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ABEO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
reduce losses and improve free cash flow yield | A supporting condition in Abeona Therapeutics, Inc.'s published investment case. The stated target is move free cash flow yield from -23% toward positive. | Broken | free cash flow yield remains below -10% next year | Valuation inputs unavailable A completed valuation measurement is required. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, early commercial-growth biotech, not an established profitable compounder. The long-term thesis is intact, with ZEVASKYN growth supporting the case, but profitability remains unproven.
The evidence labels ABEO cheap, though its valuation is 1.19 times the peer level and model confidence is low. Expectations appear broadly aligned with fundamentals, with a negative expectations gap, so the cheap label does not remove execution risk.
Near term, ZEVASKYN revenue and treatment-center growth show progress on management’s commercial priorities. However, quarterly losses widened from $17.1 million to $20.2 million, leaving the profitability goal under pressure; the next report carries elevated miss risk, and a guidance cut would be a clear setback.
Over the next several quarters, the thesis hinges on continued ZEVASKYN growth, more active treatment centers, and a credible path to profitability. Weaker jobs data could weigh on healthcare stocks, while strong results and guidance from sector bellwethers could support sector momentum.
For the next 1 to 3 years, ABEO’s long-term thesis rests on turning commercial growth into improved financial results, while elevated execution and reporting risks remain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Abeona aims to reach profitability by mid-2026 with EPS of $1.71. |
| Broken |
| EPS falls below $1.71 by 2026-06-30 |
Diluted EPS: $-0.35 per share FY2026-Q2; GAAP. Published target: >=1.71 USD_PER_SHARE. Same fiscal period as the stored target. Aug 13, 2026-0.35 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
double revenue to about $134.9M by 2027-12-31 | A primary condition in Abeona Therapeutics, Inc.'s published investment case. The stated target is >=134942830 USD. | Broken | revenue growth falls below doubling by 2027-12-31 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.07 → $-0.18 · observed estimates
$0.14B → $0.12B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-07-25 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-07-26 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-07-27 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-07-28 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-07-29 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-07-30 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-07-31 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-01 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-02 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-03 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-04 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-05 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-06 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-07 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-08 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-09 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-10 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-11 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-08-12 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-13 | $0.29 | $134,942,830 | 3 / 6 |
| 2026-08-14 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-08-15 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-08-16 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-08-17 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-08-18 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-08-19 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-08-20 | $-0.07 | $139,632,714 | 4 / 5 |
| 2026-08-21 | $-0.19 | $119,212,143 | 4 / 6 |
| 2026-08-22 | $-0.19 | $119,212,143 | 4 / 6 |
| 2026-08-23 | $-0.19 | $119,212,143 | 4 / 6 |
| 2026-08-24 | $-0.19 | $119,212,143 | 4 / 6 |
| 2026-08-25 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-08-26 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-08-27 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-08-28 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-08-29 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-08-30 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-08-31 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-01 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-02 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-03 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-04 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-05 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-06 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-07 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-08 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-09 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-10 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-11 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-12 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-13 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-14 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-15 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-16 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-17 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-18 | $-0.19 | $118,863,000 | 4 / 6 |
| 2026-09-19 | $-0.09 | $121,217,625 | 5 / 6 |
| 2026-09-20 | $-0.09 | $121,217,625 | 5 / 6 |
| 2026-09-21 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-22 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-23 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-24 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-25 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-26 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-27 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-28 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-29 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-09-30 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-10-01 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-10-02 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-10-03 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-10-04 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-10-05 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-10-06 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-10-07 | $-0.09 | $121,217,625 | 5 / 7 |
| 2026-10-08 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-09 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-10 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-11 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-12 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-13 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-14 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-15 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-16 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-17 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-18 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-19 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-20 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-21 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-22 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-23 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-24 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-25 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-26 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-27 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-28 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-29 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-30 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-10-31 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-11-01 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-11-02 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-11-03 | $-0.18 | $115,622,125 | 5 / 7 |
| 2026-11-04 | $-0.18 | $115,622,125 | 5 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.